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Introduction: Circulating endothelial cells are increased in patients affected by systemic sclerosis (SSc) and their
number strongly correlates with vascular damage. The effects of iloprost in systemic sclerosis are only partially
known. We aimed at studying the gene expression profile of circulating endothelial cells and the effects of iloprost
infusion and gene expression in patients with systemic sclerosis.
Methods: We enrolled 50 patients affected by systemic sclerosis, 37 patients without and 13 patients with digital
ulcers. Blood samples were collected from all patients before and 72 hours after either a single day or five days
eight hours iloprost infusion. Blood samples were also collected from 50 sex- and age-matched healthy controls.
Circulating endothelial cells and endothelial progenitors cells were detected in the peripheral blood of patients
with systemic sclerosis by flow cytometry with a four-colour panel of antibodies. Statistical analysis was performed
with the SPSS 16 statistical package.Circulating endothelial cells were then isolated from peripheral blood by
immunomagnetic CD45 negative selection for the gene array study.
Results: The number of both circulating endothelial cells and progenitors was significantly higher in patients
affected by systemic sclerosis than in controls and among patients in those with digital ulcers than in patients
without them. Circulating endothelial cells and progenitors number increased after iloprost infusion. Gene array
analysis of endothelial cells showed a different transcriptional profile in patients compared to controls. Indeed,
patients displayed an altered expression of genes involved in the control of apoptosis and angiogenesis. Iloprost
infusion had a profound impact on endothelial cells gene expression since the treatment was able to modulate a
very high number of transcripts.
Conclusions: We report here that circulating endothelial cells in patients with systemic sclerosis show an altered
expression of genes involved in the control of apoptosis and angiogenesis. Moreover we describe that iloprost
infusion has a strong effect on endothelial cells and progenitors since it is able to modulate both their number
and their gene expression profile.
Introduction
Systemic sclerosis (SSc) is a rare systemic autoimmune
disease characterized by a preminent vascular endothe-
lial dysfunction, by immunological abnormalities, and by
excessive extracellular matrix accumulation leading to
fibrosis of the skin and internal organs [1].
Endothelial cell (EC) damage defines a crucial step
during the pathogenesis of vascular disorders since its
injury leads to the loss of the anti-thrombotic properties
of the vessels wall and rapidly enhances the number of
damaged circulating endothelial cells (CECs). CECs are
likely to represent those cells shed from vascular
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states [2]. They correlate with physiological markers of
endothelial damage/dysfunction and they have been
identified as a marker of vascular damage in a variety of
disorders, including malignancy, cardiovascular diseases
and autoimmune disorders such as systemic sclerosis
(SSc) and vasculitides [3-9]. In healthy subjects, CECs
are rarely detectable and probably represent the effect of
natural endothelial cells turno v e r[ 1 0 ] .T h e r e f o r e ,c o m -
plete regeneration of injured endothelium is of particu-
lar importance and may occur by migration and
proliferation of surrounding mature endothelial cells.
C E C sa r et e r m i n a l l yd i f f e r e n t i a t e dc e l l sw i t hal o w
proliferative potential and their capacity to substitute
damaged endothelial cells and to create new vessels is
relative limited [11]. Moreover accumulating evidence
indicates that bone marrow-derived progenitor cells
have the potential to differentiate into mature CECs and
they have been termed endothelial progenitor cells
(EPCs) [12-15]. As a consequence, EPCs can give an
effective contribution to endothelization and neo-vascu-
larization as shown by different studies in animal mod-
els and humans [10,16-18].
Iloprost, a chemically stable prostacyclin analog [19],
has been shown to induce long-term clinical improve-
ment in various vascular conditions, including ischemic
ulcers and pulmonary hypertension primary or second-
ary to SSc [20]. Iloprost infusion increases arteriolar dis-
tension and blood flow as a result of a vasodilating
effect. The drug inhibits platelet activation and aggrega-
tion, and leukocyte activity [21]. Iloprost therapy has
also a protective and reparatory effect by influencing
EPCs [22]. The pharmacological effect on ECs modu-
lates the adhesion molecules (E-selectin, ICAM-1,
VCAM-1) expression and growth factors release, parti-
cularly VEGF and CTGF [23,24].
The biological activity is mediated by a specific inter-
action with the I prostanoid (IP) membrane receptor
[25], the same receptor as prostaglandin I2.I l o p r o s ti sa
potent IP receptor agonist that activates adenylate
cyclase, resulting in an acute increase in intracellular
cyclic AMP. Such an increase in cAMP has profound
effects on cellular function in platelets, endothelial cells,
smooth muscle cells, fibroblasts, and in a number of dif-
ferent cell types involved in both innate and acquired
immunity [23,24,26,27]. We reasoned that such a strong
impact on the function of different cell types and parti-
cularly of endothelial cells is the result of the modula-
tion of several genes, an aspect that has never been
looked at, in vivo.
We therefore aimed to evaluate the role played by ilo-
prost infusion on circulant endothelial cell number and
to clarify the molecular effects of the treatment in
patients with SSc by studying CECs gene expression
profiling before and after the treatment. Moreover, since
digital ulcers are the key clinical manifestation of severe
vascular damage, we considered a group of patients with
skin ulcers separately, in order to evaluate whether in
this subset of patients both the numbers and the gene




We enrolled 50 patients affected by SSc: 37 without skin
ulcers and 13 with digital ulcers; 18 patients were
affected by the diffuse cutaneous form and 32 by the
limited cutaneous form of the disease. Fifty age- and
sex-matched healthy donors were enrolled as controls.
Blood samples collected in EDTA using a Vacutainer
system (Becton Dickinson, NJ, USA) were drawn from
patients before, and 72 hours after a single day or five
days of being infused with iloprost for eight hours. In
both cases the first 7 ml of blood was discarded and
blood was processed within three hours after collection.
The study was approved by the local ethics committee
(Comitato Etico per la Sperimentazione, Azienda Ospe-
daliera Universitaria di Verona) and informed written
consent was obtained from all the participants to the
study.
Detection of circulating endothelial cells and progenitors
by flow-cytometry
CECs and EPCs were directly detected in whole periph-
eral blood in EDTA by lyse-no-wash method. Two hun-
dred μL of each sample were incubated with a mixture
of monoclonal antibodies for 20 minutes at room tem-
perature after a 10-minute preincubation with a blocking
serum. Fluorescein isothiocyanate (FITC)-conjugated
anti-CD45, R-Phycoerythrin (PE)-conjugated anti-
CD146, -CD31, -CD133 and -CD34 or isotype-matched
control (IgG1), allophyco-cyanine (APC)-conjugated
anti-CD3, -CD16, -CD19 and -CD33 were used. 7-
Amino-actinomycin D (7-AAD) was added for dead
cells exclusion. Samples were also stained with anti-
CD45 FITC, anti-CD146, -CD31, -CD133, -CD34 PE,
anti-CD106 or anti-VEGFR2 APC and peridin-chlorop-
hill-protein (PerCP)-conjugated anti-CD3, -CD16,
-CD19 and -CD33.
All reagents were purchased from Becton Dickinson
(San Jose, CA, USA), except for anti-CD16 (Caltag, Bur-
lingame, CA, USA), anti-CD106 (Biolegend, San Diego,
CA, USA) and anti-VEGFR2-APC (R & D Systems, Min-
neapolis, MN, USA).
After labeling, red blood cells were lysed by incubation
with 2 ml of ammonium chloride solution. The samples
were analysed on a FACS Calibur cytometer (Becton
Dickinson). The sensitivity of fluorescence detectors was
Tinazzi et al. Arthritis Research & Therapy 2010, 12:R131
http://arthritis-research.com/content/12/4/R131
Page 2 of 15set and monitored using Calibrite Beads (Becton Dickin-
son) according to the manufacturer’s recommendations;
500.000 cells per sample were acquired in live gating.
FlowJo 8.8.2 software (Tree Star, Ashland, OR, USA)
was used to analyze data. A sequential Boolean gating
strategy [28], designed to remove dead cells, platelet
aggregates and debris, and to exclude CD45 + and CD3
+/CD19 +/CD16 +/CD33 + hematopoietic cells (dump
channel), was used to accurately enumerate total CECs
and EPCs [29]. The absolute number of CECs and EPCs
was established in double platform, combining the flow-
cytometrically assessed per cent cells and the white
blood cells (WBC) count assessed using a haematology
cell analyser [30].
Isolation of CECs and EPCs from peripheral blood
Twenty ml of blood obtained from all patients were
added to 40 ml of phosphate buffered saline (PBS) solu-
tion. Mononuclear cells were isolated by density gradi-
ent centrifugation using Ficoll-Paque, washed twice with
PBS and suspended in 80 μl of degassed separation buf-
fer (PBS pH 7.2, 0.5% BSA, 2 mM EDTA) per 10
7 cells.
Cells were incubated with 20 μl of anti-CD45 coated
immunomagnetics micro-beads (Miltenyi Biotech,
Auburn, CA, USA) for 15 minutes at 4°C with gentle
rotation. Bead-bound cells were then separated from
unbound cells by a magnetic sorting on LD columns
(Miltenyi). CECs and EPCs were found in the fraction of
unbound cells (CD45 low/negative). An aliquote of each
fraction was analyzed by FACS using anti-CD45 FITC,
anti-CD146/CD31/CD34/CD133 PE and 7-AAD to con-
firm the endothelial origin and quantify the possible
lymphocyte contamination.
RNA extraction
We obtained CECs and EPCs from peripheral blood
of 13 patients affected by SSc with digital ulcers and
37 patients without any skin ulcer before, and 72 hours
after, iloprost infusion. Cells within each patient’sg r o u p
were counted and pooled together for RNA extraction.
Each patient contributed to the pool with the same
number of CECs. Control RNA was extracted from cir-
culating endothelial cells (CECs + EPCs) obtained from
50 healthy donors.
Gene array analysis
Cell pellets of CECs and EPCs obtained from SSc
patients, with and without digital ulcers, before and
72 hours after iloprost infusion both after one and five
days of therapy (test samples) were used for gene array
experiments. CECs and progenitors purified from
healthy donors were used as control samples.
Isolation of total RNA, preparation of cRNA, hybridi-
zation, and scanning of probe arrays were performed
according to the protocols of the manufacturer (Affyme-
trix, Santa Clara, CA, USA) by Cogentech (Consortium
for Genomic Technologies c/o IFOM-IEO Campus,
Milano, Italy). To ensure that a sufficient amount of
cDNA was available, the RNA extracted from CECs was
subjected to a two-cycle cDNA synthesis according to
Affymetrix protocol. Biotinylated target cRNA was
hybridized to the Human Genome U133A 2.0 GeneChip
(Affymetrix). The Human Genome U133A GeneChip is
a single array representing 14,500 well-characterized
human genes and includes more than 22,000 probe sets
and 500,000 distinct oligonucleotide features.
The different gene expression patterns were analyzed
using Array Assist version 5.0 (Stratagene, La Jolla, CA,
USA), which calculates background-adjusted, normal-
ized, and log-transformed intensity values applying the
PLIER algorithm [31-33].
The PLIER method uses quartile normalization and
runs an optimization procedure which determines the
best set of weights on the perfect match (PM) and mis-
match (MM) for each probe pair. Finally, the normal-
ized, background-corrected data were transformed
to the log2 scale. A signal log2 ratio of 1.0 indicates
an increase of the transcript level by two-fold change
(2 F.C.) and -1.0 indicates a decrease by two-fold (-2 F.C.).
A signal log2 ratio of zero would indicate no change.
Genes were selected for final consideration when their
expression (F.C.) was at least two-fold different in the
test sample versus the control sample. Experiments were
performed in duplicates [34].
Selected genes were submitted to a functional classifi-
cation according to the Gene Ontology (GO) annota-
tions [35]. To find the GO terms overrepresented in our
dataset, a GO enrichment was calculated with Array
Assist that operates a statistical computation using a
hypergeometric distribution [36].
Real time RT-PCR
Total RNA was extracted from endothelial cells using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), follow-
ing manufacturer’s instructions. First-strand cDNA was
generated using the SuperScript III First-Strand Synth-
esis System for RT-PCR Kit (Invitrogen), with random
hexamers, according to the manufacturer’sp r o t o c o l .R T
product was aliquoted in equal volumes and stored at
-20°C.
PCR was performed in a total volume of 25 μlc o n -
taining 1× Taqman Universal PCR Master mix, no
AmpErase UNG and 2.5 μl of cDNA; pre-designed,
Gene-specific primers and probe sets for each gene
(BCL2 Hs99999018-m1) (ICAM1 Hs00164932-m1)
(VEGFA Hs00900055-m1) were obtained from Assay-
on-Demande Gene Expression Products (Applied Bio-
systems). Real Time PCR reactions were carried out in a
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amplifications included 10 minutes at 95°C (AmpliTaq
Gold activation), followed by 40 cycles at 95°C for
15 seconds and at 60°C for one minute. Thermocycling
and signal detection were performed with ABI Prism
7300 Sequence Detector (Applied Biosystems). Signals
were detected according to the manufacturer’si n s t r u c -
tions. This technique allows the identification of the
cycling point where PCR product is detectable by means
of fluorescence emission (Threshold cycle or Ct value).
As previously reported, the Ct value correlates to the
starting quantity of target mRNA [37]. Relative expres-
sion levels were calculated for each sample after normal-
ization against the housekeeping gene GAPDH, using
the ΔΔCt method for comparing relative fold expression
differences [38]. The data are expressed as mRNA fold.
Ct values for each reaction were determined using
TaqMan SDS analysis software. For each amount of
RNA tested triplicate Ct values were averaged. Because
Ct values vary linearly with the logarithm of the amount
of RNA, this average represents a geometric mean.
Statistical analysis
Calculations were performed with the SPSS 16 statistical
package. Comparison of CECs and EPCs levels between
healthy controls and patients affected by SSc with and
without ulcers were performed by T-test and Pearson
test. Correlations between CECs and EPCs number
before and after iloprost infusion were assessed with a
non parametric test (Wilcoxon test).
Comparison of gene expression by Real Time RT-PCR
was carried out by T-test.
Results
CECs and EPCs in patients with SSc
CECs and EPCs are extremely rare in the peripheral
blood of healthy people, representing somewhere
between 0.01% and 0.0001% of mononuclear cells
[11,29]. Flow-cytometry offers the advantage of a
rapid and accessible technique [29,30], with the avail-
ability of multiple markers as well as the possibility of
distinguishing CECs and EPCs using a small blood
volume.
Key elements for accurate detection and enumeration
of rare events in flow cytometry are the number of
events acquired and the signal to noise ratio. Collection
of a large number of events is mandatory to identify an
adequate number of a rare event population; therefore,
we stored 500,000 cells per sample in live gating. To
minimize noise, we reduced non-specific binding by pre-
incubating cells with blocking serum and doublets
acquisition by an adequate flow rate. Dead cells can be
a major source of non-specific staining by monoclonal
antibodies. A real-time viability stain (7-AAD) was used
to identify dead cells and to exclude them from analysis.
We also established a dump channel (CD3, CD16,
CD19, CD33) to exclude cells not of interest for the
analysis. Indeed, the interest of the method reported
here lies in the high intra-assay reproducibility and the
high precision in the detection of both CECs and EPCs
due to the gating strategy and to the presence of a
dump channel [39,40].
Finally, since no markers are entirely specific for
endothelial cells, we used a multicolour approach and to
maximize the signal we used the best fluorochrome (PE)
for the most critical detection. CD146 and CD31 are
useful as endothelial cell markers and were used in
combination, since both these markers are individually
expressed by other cell types, such as activated T-lym-
phocytes, pericytes, bone marrow fibroblasts, nerve
fibers and leukocytes subsets and platelet/leukocytes
aggregates respectively [41]. CD34, CD133 and VEGFR2
were used to more precisely identify EPCs.
CECs were defined as CD45 negative, CD146/CD31/
CD34 positive and CD133 negative. EPCs are greater
than CECs and are CD146/CD31 negative, CD34/
CD133 positive, CD45 low positive and VEGFR2 posi-
tive [29].
Evaluation of CECs and EPCs by flow-cytometry
showed that the number of CECs and EPCs were signifi-
cantly higher in SSc patients than in controls and that
among patients, CECs were higher in patients with cuta-
neous ulcers than in those without ulcers. The differ-
ence in CECs and EPCs numbers was statistically
significant when SSc patients were compared to healthy
controls (Table 1); such difference was significant only
for CECs in SSc patients with skin ulcers versus patients
without ulcers (Table 2). Patients with the cutaneous
limited form of the disease showed no statistical differ-
ence in CEC and EPC numbers compared to the
patients with the diffuse cutaneous form, even if FACS
analysis showed a trend towards an increased number of
CECs and EPCs in patients with the diffuse cutaneous
form (data not shown).
We observed an increased number of CECs and EPCs
in patients after iloprost infusion (Figure 1A, B) with a
statistically significant difference in CECs count only
when the comparison was performed before and
7 2h o u r sa f t e rt h ef i v ed a y s ’ iloprost infusion (P-value
Table 1 Comparison of CECs and EPCs number between
patients affected by SSc and healthy controls
SSc patients (50) Healthy controls (50) P value
CECs/mmc 689 ± 464 22 ± 17 < 0,0001
EPCs/mms 146 ± 92 1 ± 1 < 0,0001
CECs, circulating endothelial cells; EPCs, endothelial progenitor cells; SSc,
progressive systemic sclerosis.
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cant difference both after one and five days of therapy
(Table 3).
Taken together, these data indicate that the CECs and
EPCs count is significantly higher in patients compared
to healthy controls and that iloprost infusion induces a
significant enrichment in both cell populations.
Gene array analysis of endothelial cells
We decided to use a gene array approach to analyse the
transcriptional profiles of CECs in SSc patients. Since
the purification procedure allows the recovery of a very
limited amount of cells, our samples were prepared by
mixing both EPCs and CECs, therefore, from now on
and for this set of experiments, the term CECs will refer
Table 2 Comparison of CECs and EPCs number between patients with and without skin ulcers
Skin ulcers - SSc patients (33) Skin ulcers + SSc patients (17) P value
CECs/mmc 600 ± 401 968 ± 553 0.05
EPCs/mms 142 ± 93 158 ± 92 0.597
CECs, circulating endothelial cells; EPCs, endothelial progenitor cells; SSc, progressive systemic sclerosis.
Figure 1 FACS analysis of ECs detected in a patient affected by systemic sclerosis. Panel A: Before iloprost infusion; Panel B: After iloprost
infusion. Sequential four-color gating strategy. In cytogram (a) which displays all events, a rectangular region (R1) is drawn to exclude dead cells
from analysis (7-AAD positive-cells). In cytogram (b), a polygonal region (R2) is drawn to define lymphocytes on the basis of the morphological
parameter Side Scatter (SSC) and of CD45 expression. An additional region (R3), which includes all CD45 positive events, is depicted to derive
CECs and EPCs enumeration. In cytogram (c), R4 is defined as FSC (Forward Scatter)/SSC gate on lymphocytes set on FSC left-hand border and
include intermediate region between lymphocytes and monocytes. In cytogram (d) are included all events which meet morphological criteria of
R4. R5 and R6 include respectively CECs and EPCs which are shown negative for dump channel markers (CD3/CD16/CD19/CD33) in cytogram
(e). CECs and EPCs show a different staining with CD146/CD31/CD133/CD34 (ECs). Cytogram (f) shows the morphological characteristics of cells
in R5 and R6 (CECs and EPCs respectively).
Tinazzi et al. Arthritis Research & Therapy 2010, 12:R131
http://arthritis-research.com/content/12/4/R131
Page 5 of 15to the cell population that includes the two cell
subtypes.
CECs were isolated from 37 patients without ulcers
and from 13 patients with ulcers. CECs obtained from
each group of subjects were then pooled for RNA
extraction. Each patient contributed to the pooled sam-
ple with the same number of cells. CECs were also iso-
lated from the blood of 50 healthy donors.
We compared the gene expression patterns of CECs
obtained from SSc patients either in presence or in
absence of digital ulcers with those obtained from nor-
mal healthy donors. As described in the Methods sec-
tion only those genes modulated more than two-fold
compared to the control sample (normal healthy
donors) were considered in our analysis.
All the results of the gene array analysis have been
deposited in the public repository ArrayExpress (acces-
sion number: [E-MEXP-2769]).
In CECs from patients with ulcers 6,544 genes were
modulated when compared to the healthy counterpart,
in particular 5,260 transcripts were down-regulated and
1,284 genes were up-regulated (Additional files 1, 2, 3).
A profound difference in gene expression was also
observed in CECs obtained from patients without
ulcers with 6,672 modulated genes (5,425 down-regu-
lated genes and 1,247 up-regulated genes) (Additional
files 4, 5).
These data showed that the transcriptional profiles of
CECs in SSc were profoundly different from the tran-
scriptional profiles of CECs of healthy donors, indicating
that the two populations were quite heterogeneous at
least at transcriptional level.
Among the genes differently expressed in these two
populations, the number of down-regulated genes was
significantly higher when compared to the number of
the up-regulated ones.
CECs were also obtained from the same patients
72 hours after treatment with iloprost and the gene expres-
sion profiles of these cells were compared to the ones of
CECs obtained from the same patients before treatment.
The treatment resulted in differential expression of 2,133
genes (1,080 up-regulated and 1,053 down-regulated)
in patients with digital ulcers (Additional files 6, 7). A
higher number of genes (6,643) was modulated by the ilo-
prost infusion in patients without digital ulcers: the up-
regulated were 5,081, while the down-regulated ones were
1,562 (Additional files 8, 9).
The results so far obtained showed that iloprost treat-
ment had a strong impact on the transcriptional activity
of CECs derived from SSc patients with and without
digital ulcers.
Given the high number of modulated genes, we next
decided to focus our attention on the effect of the treat-
ment on the genes differently expressed in patients
affected by SSc versus healthy donors. We therefore
selected within the 6,544 transcripts differently
expressed in patients with digital ulcers only those genes
which were also modulated after iloprost treatment in
the same patients. This subset of genes included 1,211
transcripts.
We then performed a Gene Ontology (GO) analysis to
cluster genes into functional classes according to GO
biological processes and molecular functions and
selected the functional classes overrepresented among
the differentially expressed genes (GO term enrichment).
The modulated genes belong to several functional
classes including: positive regulation of anti-apoptosis,
response to stress, response to wounding and wound
healing, Wnt receptor activity, receptor complex, mem-
brane, chemotaxis, DNA-dependent DNA replication,
prostaglandin-reductase activity, G0 to G1 phase transi-
tion, platelet-derived growth factor beta-receptor activ-
ity, actin cytoskeleton organization and biogenesis,
innate immune response. Representative examples of
such genes within the above mentioned functional
classes are presented in a compiled form in Table 4
which includes Gene Bank accession numbers and F.C.
of expression of the genes.
Noteworthy is that most of these genes showed a sig-
nificant change at transcription level after iloprost
infusion.
Among genes related to apoptosis, for instance, anti-
apoptotic genes such as RAS p21 protein activator 1
(RASA1), protein-kinases, AMP-activated alpha1
(PRKAA1) and BCL2 interacting protein 3 (BNIP3) were
down-regulated in sclerodermic patients (F.C. -8.72,
-6.49 and -69.05 respectively) but up-regulated after
treatment (F.C. + 4.29, + 6.61, + 11.78).
Genes involved in the cellular response to stress had a
similar behaviour; CD59, a complement regulatory pro-
tein, was strongly down-regulated in SSc patiens (F.C.
-18.77) and up-regulated by the treatment (F.C. + 2.72).
Vascular endothelial growth factor (VEGF) a well-
known mitogen for vascular endothelial cells and a fun-
damental molecule for the EPCs recruitment from bone
marrow, was greatly repressed in SSc patients (FC
Table 3 Number of CECs and EPCs before and after
iloprost infusion
CECs/mmc EPCs/mmc
Data before iloprost infusion 661 ± 404 152 ± 93
Data 72 h after one day iloprost therapy 745 ± 453 186 ± 104
¶
Data 72 h after five days iloprost therapy 775 ± 382 206 ± 139
¥
* P-value 0.368 vs cells number before iloprost infusion
# P-value 0.004
¶ P-value 0.015
¥ P- value 0.014
CECs, circulating endothelial cells; EPCs, endothelial progenitor cells.
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Positive regulation of anti-apoptosis
210621_s_at RAS p21 protein activator (GTPase
activating protein) 1
RASA1 8.72 down 4.28 up M23612
214917_at protein kinase, AMP-activated, alpha 1
catalytic subunit
PRKAA1 6.49 down 6.60 up AK024252
201849_at BCL2/adenovirus E1B 19 kDa interacting
protein 3
BNIP3 69.04 down 11.78 up NM_004052
Response to stress
200985_s_at CD59 molecule, complement regulatory
protein
CD59 18.76 down 2.72 up NM_000611
202906_s_at nibrin NBN 12.38 down 4.28 up AF049895
206040_s_at mitogen-activated protein kinase 11 MAPK11 17.27 up 10.62 down NM_002751
209305_s_at growth arrest and DNA-damage-inducible.
beta
GADD45B 13.58 down 8.27 down AF078077
210512_s_at vascular endothelial growth factor VEGF 36.08 down 5.58 up AF022375
213756_s_at heat shock transcription factor 1 HSF1 8.12 up 3.47 down AI393937
217684_at thymidylate synthetase TYMS 4.21 down 3.30 up BG281679
220038_at serum/glucocorticoid regulated kinase
family. member 3
SGK3 8.24 down 9.60 down NM_013257
Response to wounding and wound healing
209277_at Tissue factor pathway inhibitor 2 TFPI2 9.85 down 2.62 up AL574096
203294_s_at lectin, mannose-binding, 1 LMAN1 11.53 up 9.84 down U09716
205767_at epiregulin EREG 5.13 down 3.61 down NM_001432
209101_at connective tissue growth factor CTGF 595.44 down 14.43 up M92934
Wnt receptor activity
203987_at frizzled homolog 6 FZD6 39.71 down 2.18 up NM_003506
Receptor complex
201474_s_at integrin. alpha 3 ITGA3 5.21 down 2.36 up NM_002204
204625_s_at integrin. beta 3 ITGB3 2.17 up 2.47 down BF115658
206009_at integrin. alpha 9 ITGA9 3.18 down 3.58 down NM_002207
211772_x_at cholinergic receptor. nicotinic. alpha 3 CHRNA3 2.54 up 4.46 down BC006114
204773_at interleukin 11 receptor. alpha IL11RA 15.25 down 2.90 down NM_004512
membrane
202637_s_at intercellular adhesion molecule 1 (CD54) ICAM1 28.90 down 6.61 up AI608725
203699_s_at deiodinase, iodothyronine, type II DIO2 7.75 up 10.10 down U53506
203988_s_at fucosyltransferase 8 (alpha (1,6)
fucosyltransferase)
FUT8 17.44 down 17.71 up NM_004480
204273_at endothelin receptor type B EDNRB 10.11 up 2.75 down NM_000115
205421_at solute carrier family 22, member 3 SLC22A3 6.50 up 6.21 down NM_021977
213856_at CD47 molecule CD47 12.43 down 10.98 up BG230614
Chemotaxis
205242_at chemokine (C-X-C motif) ligand 13 CXCL13 3.03 down 7.56 up NM_006419
209687_at chemokine (C-X-C motif) ligand 12 CXCL12 24.98 down 2.54 up U19495
210845_s_at plasminogen activator, urokinase receptor PLAUR 12.79 down 2.05 up U08839
207850_at chemokine (C-X-C motif) ligand 3 CXCL3 24.57 down 3.15 down NM_002090
210163_at chemokine (C-X-C motif) ligand 11 CXCL11 34.76 down 5.60 up AF030514
215723_s_at phospholipase D1, phosphatidylcholine-
specific
PLD1 12.37 down 3.08 up AJ276230
219825_at cytochrome P450, family 26, subfamily B,
polypeptide 1
CYP26B1 17.74 down 15.25 up NM_019885
DNA-dependent DNA replication
205085_at origin recognition complex, subunit 1-like ORC1L 10.43 down 7.25 up NM_004153
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treatment.
The high increase of heat shock transcription factor 1
(HSF1) (F.C. + 8.12) was followed by a marked reduc-
tion (F.C. -3.47) after iloprost treatment.
Another cluster of modulated genes was represented
by genes involved in the process of wounding and
wound healing. Tissue factor pathway inhibitor-2
(TFPI2) is regulated by vascular endothelial growth fac-
tor and indeed its expression profile varied similarly to
VEGF (F.C. -9.85 before and F.C. + 2.62 after iloprost).
Indeed connective tissue growth factor (CTGF) showed
the strongest down-regulation in SSc patients (F.C.
-595.44) which was followed by a marked up-regulation
(F.C. + 14.43) after treatment.
Iloprost also influenced the adhesion properties of
CECs since several integrin genes were modulated in
SSc patients after treatment. Expression level of inter-
cellular adhesion molecule 1 (ICAM1) varied from a
down-regulation of -28.91 F.C. to an up-regulation of
+ 6.61 F.C. The transcription level of endothelin recep-
tor type B (EDNRB) gene varied from F.C. + 10.11 to
F.C. -2.75.
The functional class named chemotaxis included genes
encoding for chemokines, a group of molecules able to
attract leukocytes and regulate angiogenesis, vascular
proliferation and fibrosis. Several genes encoding for
chemokines (CXCL13, CXCL12; CXCL3, CXCL11) had
a significant change at the transcription level after ilo-
prost infusion.
The CECs transcriptome modulated by iloprost treat-
ment was also enriched in transcripts involved in the
innate immune response regulation. This functional
class included several toll like receptors (TLR2, 3 and 5)
in particular TLR3 and TLR5 expression underwent
extensive variation in SSc patients after iloprost infusion
(F.C. -55.82 and -27.49 before treatment to F.C. -6.59
and + 2.03 after treatment).
Table 4 Functional classification of genes modulated by iloprost in SSc patients with digital ulcers (Continued)
208070_s_at REV3-like, catalytic subunit of DNA
polymerase zeta
REV3L 38,90 down 2.80 down NM_002912
208808_s_at high-mobility group box 2 HMGB2 5.53 down 2.41 up BC000903
209084_s_at RAB28, member RAS oncogene family RAB28 23.27 down 2.09 up BE504689
210892_s_at general transcription factor II, i GTF2I 3.72 down 3.64 up BC004472
DNA-dependent DNA replication
205085_at carbonyl reductase 1 CBR1 2.39 up 2.34 down BC002511
G0 to G1 transition
205655_at Mdm4, p53 binding protein MDM4 3.27 down 6.07 up NM_002393
platelet-derived growth factor beta-receptor activity
205226_at platelet-derived growth factor receptor-
like
PDGFRL 5.33 up 9.50 down NM_006207
actin cytoskeleton organization and biogenesis
209209_s_at pleckstrin homology domain containing,
family C, member1
PLEKHC1 51.02 down 13.59 up AW469573
216621_at Rho-associated, coiled-coil containing
protein kinase 1
ROCK1 8.58 down 8.52 up AL050032
220997_s_at diaphanous homolog 3 (Drosophila) DIAPH3 3.72 down 10.53 up NM_030932
208614_s_at filamin B, beta (actin binding protein 278) FLNB 59.49 down 2.91 down M62994
214925_s_at spectrin, alpha, non-erythrocytic 1 (alpha-
fodrin)
SPTAN1 13.23 down 2.62 down AK026484
215602_at FYVE, RhoGEF and PH domain containing
2
FGD2 12.94 up 2.60 down AK024456
Innate immune response
204924_at toll-like receptor 2 TLR2 5.94 down 3.16 up NM_003264
206271_at toll-like receptor 3 TLR3 55.81 down 6.59 down NM_003265
206206_at CD180 molecule CD180 23.53 down 10.73 up NM_005582
210166_at toll-like receptor 5 TLR5 27.49 down 2.03 up AF051151
215388_s_at complement factor H CFH 561.66 down 2.36 down X56210
206157_at pentraxin-related gene, rapidly induced
by IL-1 beta
PTX3 5.17 down 12.45 up NM_002852
206693_at interleukin 7 IL7 3.06 down 11.97 up NM_000880
206727_at complement component 9 C9 6.43 up 9.24 down K02766
SSc, progressive systemic sclerosis
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Page 8 of 15A very strong reduction in expression (F.C. -561.66) of
t h eg e n ee n c o d i n gf o rc o m p l e m e n tf a c t o rH( C F H )w a s
observed in CECs during SSc, however such reduction
was less pronounced (F.C. -2.36) after iloprost infusion.
The same analysis was performed on CECs isolated
from SSc patients without digital ulcers. Therefore we
focused our attention on the genes significantly modu-
lated in SSc patients, whose expression was also influ-
enced by iloprost treatment.
Using these criteria we identified 3,990 genes, which
were stratified over a large number of different func-
tional classes of genes. The results are presented in
compiled form in Table 5, bold characters indicate
genes also present in SSc with digital ulcers. A large
number of such transcripts were ascribed to the same
functional classes analyzed for SSc with digitals ulcers.
We found that genes belonging to these GO categories
were therefore modulated in both disease subsets (with
or without digital ulcers).
Noteworthy was that most of the selected genes had a
similar response to iloprost infusion when compared to
the other disease subset. The results further confirm
that iloprost treatment exerts a strong effect on the
transcriptional profiles of CECs obtained from SSc
patients.
Finally, we compared the gene expression profiles of
CECs from the two subsets of SSc patients and found
that 2,303 genes were significantly modulated in SSc
with digital ulcers as compared to SSc without digital
ulcers. The Gene Ontology analysis of these transcripts
revealed a functional enrichment (P < 0.02) in several
gene categories including immune response, response to
wounding and inflammatory response (Table 6).
Interestingly, iloprost treatment modulated 59.5% of
these transcripts (1,370/2,303).
These data show that there is a significant difference
in the trascriptional profiles of CECs isolated from SSc
patients with or without digital ulcers. The results there-
fore indicate that CECs are quite heterogeneous within
the same disease and that these differences may be asso-
ciated to the presence of a particular clinical subset.
Real Time RT-PCR validation of gene array results
We validated the results obtained with the gene array by
Real Time RT-PCR using the same endothelial total
RNA extract that was used for the gene array analysis.
The Real Time RT-PCR results were concordant with
the array results in three of three genes tested in the
two subsets studied, in terms of significant differences
in gene expression between CECs derived from patients
affected by SSc with and without skin ulcers before and
after iloprost infusion. The genes subjected to validation
included those encoding VEGF, ICAM-1 and BCL-2
(Figure 2). GAPDH was selected as endogenous
standard, and we saw no significant changes in the Q-
PCR results when the data were normalized using beta-
actin, another constitutively transcribed gene.
Discussion
We have detected and quantified CECs and EPCs in the
peripheral blood of 50 SSc patients using a four-color
flow-cytometry approach. The gating strategy and the
presence of a dump channel allows the detection of
both CECs and EPCs with high precision and a high
intra-assay reproducibility. Moreover, we have followed
the EULAR recommendations on endothelial precursor
cells quantification [42]. Most of the reports on CECs
and EPCs enumeration have used a three-color flow-
cytometry [6,43] and different markers from those
recommended by EULAR explaining the controversial
results obtained by different groups [6,44]. We needed a
precise enumeration of CECs and EPCs also because we
had to use them for the gene array study.
In our cohort of SSc patients, the number of both
CECs and EPCs was higher than in healthy donors as
already reported [6]. The increased EPC levels in SSc
support their mobilisation from bone marrow in the
attempt of revascularization in response to vascular
ischemia. Moreover the counts of CECs correlated with
the clinical stage of the disease, since a higher number
was detectable in patients with a more severe vascular
damage (presence of digital ulcers). Patients with digital
vascular lesions did not show a significant increased
number of EPCs in accordance with previous data [45]
and suggesting an increased homing at this stage.
W eo b s e r v e dt h a ti l o p r o s ti n f u s i o ns i g n i f i c a n t l y
increased the number of both cell types in all the
patients treated. To our knowledge, the finding of
increased levels of CECs and EPCs in patients with SSc
after iloprost treatment has not been previously reported
and may be of difficult interpretation since one would
expect a reduction of these cells to the levels similar to
t h o s es e e ni nh e a l t h yc o n t r o ls. A possible explanation
for these findings is that iloprost infusion may be
responsible for the in vivo recruitment of EPCs from
bone marrow and for their homing into sites of angio-
genesis and/or vascular damage, thus contributing to
neovascularization and/or wound-healing processes.
Moreover, the drug may favour the migration and pro-
liferation of mature endothelial cells surrounding the
sites of vascular damage thus leading to an increase
shedding of damaged cells. However, the increase of
EPCs is not confined to iloprost therapy since a statisti-
cally significant increase in EPCs has also been observed
during atorvastatin treatment in patients with SSc [43].
In SSc patients, CECs were not only increased in their
number but also revealed a completely different tran-
scriptional profile when compared to that of CECs
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Positive regulation of anti-apoptosis
201849_at BCL2/adenovirus E1B 19 kDa interacting
protein 3
BNIP3 19.65 down 5.93 up NM_004052
210621_s_at RAS p21 protein activator (GTPase activating
protein) 1
RASA1 5.35 down 2.02 up M23612
214917_at protein kinase, AMP-activated, alpha 1
catalytic subunit
PRKAA1 2.88 down 3.50 up AK024252
Response to stress
202906_s_at nibrin NBN 3.83 down 4.33 up AF049895
206040_s_at mitogen-activated protein kinase 11 MAPK11 3.53 up 2.15 up NM_002751
209305_s_at growth arrest and DNA-damage-inducible,
beta
GADD45B 11.23 down 4.25 up AF078077
210512_s_at vascular endothelial growth factor VEGF 7.03 down 2.38 up AF022375
217684_at thymidylate synthetase TYMS 2.76 down 5.84 up BG281679
Response to wounding and wound healing
209101_at connective tissue growth factor CTGF 1912.1 down 11.18 up M92934
209277_at Tissue factor pathway inhibitor 2 TFPI2 3.36 down 8.90 down AL574096
Wnt receptor activity
203987_at frizzled homolog 6 FZD6 19.85 down 3.25 up NM_003506
Receptor complex
201474_s_at integrin, alpha 3 ITGA3 3.37 down 2.04 up NM_002204
206009_at integrin, alpha 9 ITGA9 2.05 down 2.02 up NM_002207
211772_x_at cholinergic receptor, nicotinic, alpha 3 CHRNA3 2.10 up 12.73 down BC006114
204773_at interleukin 11 receptor, alpha IL11RA 10.76 down 6.66 up NM_004512
Membrane
202638_s_at intercellular adhesion molecule 1 (CD54) ICAM1 21.89 down 2.00 up NM_000201
204273_at endothelin receptor type B EDNRB 12.18 up 9.07 up NM_000115
205421_at solute carrier family 22, member 3 SLC22A3 14.37 up 8.31 down NM_021977
213857_s_at CD47 molecule CD47 6.17 down 3.51 up BG230614
Chemotaxis
207850_at chemokine (C-X-C motif) ligand 3 CXCL3 35.50 down 2.32 up NM_002090
211122_s_at chemokine (C-X-C motif) ligand 11 CXCL11 2.98 down 2.32 down AF002985
215723_s_at phospholipase D1, phosphatidylcholine-
specific
PLD1 7.72 down 2.07 up AJ276230
219825_at cytochrome P450, family 26, subfamily B,
polypeptide 1
CYP26B1 25.09 down 3.98 down NM_019885
203218_at mitogen-activated protein kinase 9 MAPK9 9.53 down 7.02 up W37431
DNA-dependent DNA replication
208070_s_at REV3-like, catalytic subunit of DNA
polymerase zeta
REV3L 21.36 down 8.90 up NM_002912
208808_s_at high-mobility group box 2 HMGB2 2.78 down 3.18 up BC000903
209084_s_at RAB28, member RAS oncogene family RAB28 7.25 down 3.79 up BE504689
213336_at General transcription factor II, i GTF2I 4.51 down 4.52 up AI826454
Prostaglandin-E2 9-reductase activity
50221_at transcription factor EB TFEB 6.09 down 11.09 up AI524138
G0 to G1 transition
210386_s_at metaxin 1 MTX1 6.35 down 4.85 up BC001906
platelet-derived growth factor beta-receptor activity
205226_at platelet-derived growth factor receptor-like PDGFRL 5.04 up 2.72 up NM_006207
actin cytoskeleton organization and biogenesis
208614_s_at filamin B, beta (actin binding protein 278) FLNB 92.27 down 2.75 up M62994
214925_s_at spectrin, alpha, non-erythrocytic 1 (alpha-
fodrin)
SPTAN1 17.80 down 8.95 up AK026484
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Page 10 of 15obtained from healthy donors. We decided to focus our
attention on the different expression of genes strictly
related to vasculogenesis, reparative processes, cell
migration and homing, since a deficient vascular repair
mechanism and defective vasculogenesis are the main
contributors to vasculopathy in Ssc.
We found a significant decrease in expression of genes
encoding for molecules involved in the negative regula-
tion of apoptosis (RASA1, PRKAA1 and BNIP3) sug-
gesting that the cells are prone to apoptosis. Apoptosis
of endothelial cells is considered the primary pathogenic
event in SSc and the downmodulation of genes encoding
for antiapoptotic molecules helps in understanding the
molecular basis of this event. Moreover, the downregu-
lation of SGK3, also called cytokine-independent survi-
val kinase (CISK), a survival kinase involved in cellular
response to stress protecting cells from apoptosis [46],
further indicates an impaired regulation of cellular survi-
val pathways.
In SSc patients CECs showed also a decreased tran-
scription of TFPI2, EREG and CTGF, molecules
crucially involved in tissue-specific proliferation/differ-
entiation homeostasis and effective reparative activity,
indicating that these cells are also compromised in their
wound healing capacity. CTGF, a growth factor pro-
duced as part of a growth factor cascade during vascular
injury responses, can also modulate the activity of angio-
genic molecules such as VEGF [47,48] and similarly,
VEGF is a potent inducer of CTGF mRNA [49,50].
Therefore the simultaneous under-expression of both
genes is not surprising.
Another function severely compromised in SSc is the
adherence ability of CECs, demonstrated by the reduced
transcription levels of several adhesion molecules such
as ICAM1 and integrins. This aspect together with the
downregulation of different chemokines may suggest a
reduced cell migration and therefore a reduced
andothelial cell homing. In particular, the reduced
expression of CXCL12 (SDF1) in patients with digital
u l c e r si si na c c o r d a n c ew i t hp r e v i o u sf i n d i n g so nt h e
reduced expression of this chemokine in late phase of
the disease [51].
Table 5 Functional classification of genes modulated by iloprost in SSc patients without digital ulcers (Continued)
215602_at FYVE, RhoGEF and PH domain containing 2 FGD2 15.22 down 5.67 up AK024456
Innate immune response
206271_at toll-like receptor 3 TLR3 8.66 down 10.24 down NM_003265
210166_at toll-like receptor 5 TLR5 7.83 down 2.95 up AF051151
215388_s_at complement factor H CFH 295.64 down 3.15 down X56210
206693_at interleukin 7 IL7 10.94 down 2.96 up NM_000880
203854_at complement factor I CFI 578.23 down 16.50 up NM_000204
206727_at complement component 9 C9 11.81 down 10.01 up K02766
SSc, progressive systemic sclerosis
Table 6 Functional enrichment in gene categories in patients with skin ulcers compared to those without ulcers
Biological process Number of probe sets P-value
Immune response 210 0.0000000009
Defense response 221 0.0000000145
Response to wounding 109 0.0000012730
Signal transducer activity 472 0.0000206037
Response to stress 236 0.0000215677
Regulation of cell proliferation 89 0.0000403309
Positive regulation of nitric oxide biosynthesis 8 0.0001150065
Positive regulation of biosynthesis 16 0.0001813324
Receptor activity 290 0.0003570920
Cell activation 36 0.0005153290
Cell proliferation 137 0.001020579
Positive regulation of innate immune response 3 0.001302911
Regulation of immune response 27 0.001521656
Inflammatory response 47 0.002011958
Positive regulation of immune response 20 0.002900865
Cell adhesion 136 0.006908177
Cytokine activity 47 0.017808983
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Page 11 of 15Endothelin-1 and its receptors A and B play a pivotal
role both in vasoconstriction and in fibrosis. Receptors
A are expressed on smooth muscle cells and mediate
vasoconstriction, whereas receptors B are expressed on
endothelial cells and mediates primarily vasodilatation
through nitric oxide production. The upregulation of
endothelin-1 receptor B gene expression by CECs sug-
gests the attempt of endothelial cells to privilege the
vasoactive effect and to increase tissue blood flow.
VEGF, a potent angiogenic mitogen playing a crucial
role in angiogenesis under various pathophysiological
conditions, was strongly down-regulated probably in
relation to a reduced proangiogenic activity of CECs in
SSc. Interestingly VEGF can mobilize EPCs from bone
marrow and accelerate endothelial damage repair
[52,53]. Therefore the increase in VEGF gene expression
after iloprost therapy may explain the EPCs increase in
an attempt to repair the vascular damage. The increase
of the VEGF gene expression after iloprost stimulation
has already been described in lung fibroblasts [24].
Moreover iloprost has been reported to induce VEGF
production from intestinal epithelial cells [54], from
monocytes [55] and to modulate VEGF secretion from
platelets isolated from SSc patients [56]. It is well
known that VEGF has been found elevated in the sera
of patients with SSc. However, we must consider first of
all that the gene array analysis has been carried out in
CECs, which can exhibit a different transcriptional pro-
file from that expected and seen in the same cells in dif-
ferent conditions, that is, cells isolated from skin and
coltured [57] or in a whole tissue [58]. Secondly, VEGF
is produced from different cell types as mentioned
above and this may account at least in part for the
increased levels of circulant VEGF in patients with SSc.
As for VEGF gene expression, iloprost infusion showed
a strong effect on the transcriptional profiles of CECs
isolated from patients with SSc both in the presence or
absence of digital ulcers, since it induced a marked
modulation of the differently expressed genes.
When we considered the genes over- and under-
expressed in SSc patients versus healthy donors we
found that the treatment induced an opposite behaviour
of most of these transcripts. Thus several molecular
functions repressed in CECs of scleroderma patients,
were restored after iloprost infusion as shown by the
over-expression of antiapoptotic genes (RASA1,
PRKAA1 and BNIP3) and of the transcripts encoding
for adhesion molecules (ICAM1, ITGA3, ITGA9), che-
mokines and wound healing process (EREG, CTGF).
Also, the decrease in heat shock transcription factor 1
expression after iloprost treatment is in accordance with
the protective effects of the drug on endothelial cells.
The gene array data concerning the drug modulation of
genes involved in the control of apoptosis, in cell adhe-
sion and in vasculogenesis were validated by quantitative
RT-PCR of selected genes (BCL2, ICAM1, VEGF) in SSc
patients with and without digital ulcers.
Conclusions
In this study we analyzed gene expression profiles of
CECs and EPCs obtained from healthy subjects and
from SSc patients with and without digital ulcers before
Figure 2 Validation of gene array results by Real Time RT-PCR. Genes selected for validation by Real Time RT-PCR in CECs before (bar 1)
and after (bar 2) iloprost infusion in SSc patients without (panel A) and with (panel B) digital ulcers. ICAM-1, Bcl2 and VEGF transcripts were
increased several times after iloprost infusion in both groups of patients. The increase was statistically significant (P < 0.05) in all cases. The
experiments were carried out in triplicates.
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Page 12 of 15and after iloprost treatment using a gene array
approach. Based on gene ontology analysis we found
that CECs from patients show down-modulation of
genes involved in the control of apoptosis, in cell migra-
tion and adhesion and in angiogenesis. Several impaired
cellular function were reversed by iloprost treatment
and the gene array modulation was validated by quanti-
tative RT-PCR of selected genes. The different expres-
sion profile of CECs in SSc patients compared to
normal subjects account for endothelial cell apoptosis
and for the impaired angiogenesis in the disease. More-
over, our data give a novel insight into the vascular
repairing effects of iloprost treatment.
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Additional file 1: Gene expression profile in healthy subjects. Raw
intensity signal values obtained from the sample of healthy subjects.
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